Growth factor regulation of secreted matrix metalloproteinase and plasminogen activators in prostate cancer cells, normal prostate fibroblasts and normal osteoblasts

Prostate Cancer Prostatic Dis. 2003;6(2):148-53. doi: 10.1038/sj.pcan.4500640.

Abstract

We assessed the relative levels of secreted matrix metalloproteinases (MMPs) and plasminogen activators (PAs) in PC-3 cells, prostate fibroblasts and osteoblasts in the presence and absence of VEGF, TGF beta1 and bFGF. Fibroblasts and osteoblasts secreted more MMPs -1 and -2 than did PC-3 cells, while PC-3 s contributed the majority of PAs. MMP-1 expression was downregulated by transforming growth factor beta-1 (TGF beta1) treatment in prostate fibroblasts and upregulated by basic fibroblast growth factor (bFGF) in both stromal lines. In PC-3 cells, TGF beta1 and bFGF increased urokinase plasminogen activator secretion. TGF beta1 decreased tissue plasminogen activator secretion in all cell lines. Prostate cancer cells associated with fibroblasts or osteoblasts have a variety of MMPs and PAs to facilitate matrix degradation.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Extracellular Matrix / metabolism
  • Fibroblast Growth Factor 2 / pharmacology*
  • Fibroblasts / physiology
  • Male
  • Matrix Metalloproteinases / metabolism*
  • Osteoblasts / physiology*
  • Plasminogen Activators / metabolism*
  • Prostate / cytology*
  • Prostatic Neoplasms / pathology*
  • Transforming Growth Factor beta / pharmacology*
  • Tumor Cells, Cultured
  • Up-Regulation
  • Vascular Endothelial Growth Factor A / pharmacology*

Substances

  • Transforming Growth Factor beta
  • Vascular Endothelial Growth Factor A
  • Fibroblast Growth Factor 2
  • Plasminogen Activators
  • Matrix Metalloproteinases